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Disturbances in Ca2+ homeostasis and mitochondrial dysfunction have emerged as major
pathogenic features in familial and sporadic forms of Amyotrophic Lateral Sclerosis
(ALS), a fatal degenerative motor neuron disease. However, the distinct molecular ALS-
pathology remains unclear. Recently, an activity-dependent Ca2+ homeostasis deficit,
selectively in highly vulnerable cholinergic motor neurons in the hypoglossal nucleus
(hMNs) from a common ALS mouse model, the endstage superoxide dismutase
SOD1G93A transgenic mouse, was described. This functional deficit was defined by a
reduced hMN mitochondrial Ca2+ uptake capacity and elevated Ca2+ extrusion across
the plasma membrane. To address the underlying molecular mechanisms, here we
quantified mRNA-levels of respective potential mitochondrial and plasma membrane
Ca2+ transporters in individual, choline-acetyltransferase (ChAT) positive hMNs from
wildtype (WT) and endstage SOD1G93A mice, by combining UV laser microdissection with
RT-qPCR techniques, and specific data normalization. As ChAT cDNA levels as well as
cDNA and genomic DNA levels of the mitochondrially encoded NADH dehydrogenase
ND1 were not different between hMNs from WT and endstage SOD1G93A mice, these
genes were used to normalize hMN-specific mRNA-levels of plasma membrane and
mitochondrial Ca2+ transporters, respectively. We detected about 2-fold higher levels
of the mitochondrial Ca2+ transporters MCU/MICU1, Letm1, and UCP2 in remaining
hMNs from endstage SOD1G93A mice. These higher expression-levels of mitochondrial
Ca2+ transporters in individual hMNs were not associated with a respective increase in
number of mitochondrial genomes, as evident from hMN specific ND1 DNA quantification.
Normalized mRNA-levels for the plasma membrane Na+/Ca2+ exchanger NCX1 were also
about 2-fold higher in hMNs from SOD1G93A mice. Thus, pharmacological stimulation
of Ca2+ transporters in highly vulnerable hMNs might offer a neuroprotective strategy
for ALS.
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INTRODUCTION
Amyotrophic Lateral Sclerosis (ALS) is the most common motor
neuron (MN) degenerative disease, with an adult onset and an
annual incidence of 1–3 cases per 100,000 people worldwide
(Ludolph et al., 2012; Valori et al., 2014). Typical histopathologi-
cal hallmark of ALS is the loss of upper and lower motor neurons,
which is accompanied by reactive gliosis (Valori et al., 2014).
Although first described in 1869 (Charcot and Joffroy, 1869), the
causes of ALS remain largely unknown and, as effective long-
term treatment strategies are not available, most patients die 3–5
years after symptom-onset (Hardiman et al., 2011; Vucic et al.,
2014). There is a family history in around 10% of ALS patients,
that can be attributed to several gene defects (Renton et al.,
2013). Most common is an abnormal hexanucleotide expansion
of the chromosome 9 open reading frame 72 gene (C9ORF72),
present in many familial as well as some sporadic ALS cases
(DeJesus-Hernandez et al., 2011; Renton et al., 2011; Haeusler
et al., 2014). However, causes for neurodegeneration in most spo-
radic ALS patients still remain mostly unresolved (Vucic et al.,
2014). Disease mechanisms of both, sporadic and familial ALS,
share common pathogenetic features, in particular glutamate
excitotoxicity, calcium (Ca2+) overload, mitochondrial dysfunc-
tion, oxidative stress and protein dysfunction and/or aggregation,
e.g., particularly of the 43-kDa trans-activating response region
binding protein (TDP-43) or cytoplasmic Cu2+/Zn2+-superoxide
dismutase 1 (SOD1) (Neumann et al., 2006; Ilieva et al., 2009;
Ferraiuolo et al., 2011; Lee et al., 2012; Matus et al., 2013;
Rotunno and Bosco, 2013; Muyderman and Chen, 2014; Tadic
et al., 2014). There is also strong evidence for a crucial role of
astroglia cells for MN degeneration in ALS (Valori et al., 2014).
In both, ALS patients and its transgenic animal models, there is
evidence of ubiquitinated protein inclusions in MNs as well as
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in glial cells (Bruijn et al., 1997; Pasinelli et al., 2000; Mendonça
et al., 2006).
Independent of the cause of ALS, one neuro-pathological
hallmark of the disease is the differential vulnerability of MN
populations to neurodegenerative triggers, e.g., MNs in spinal
cord or hypoglossal nucleus are particularly vulnerable to ALS-
trigger factors, while other MN populations, e.g., in particular
in the oculomotor nucleus, remain relatively spared (Cleveland
and Rothstein, 2001; Kanning et al., 2010; Kaplan et al., 2014).
Vulnerable MNs display low endogenous Ca2+ buffering capac-
ity due to a lack of cytosolic Ca2+ binding proteins (like
calbindind28k or parvalbumin) (von Lewinski and Keller, 2005),
accompanied by expression of AMPA glutamate receptor sub-
types that are highly permeable to Ca2+ (Van Den Bosch
et al., 2000; Grosskreutz et al., 2010). Thus, these vulnera-
ble MNs depend particularly on mitochondrial Ca2+ uptake to
recover from transient Ca2+ increase during electrical activity
(Grosskreutz et al., 2007; Jaiswal and Keller, 2009). However,
mitochondria in highly vulnerable MNs show substantial func-
tional and morphological changes in ALS animal models and
human patients (Kawamata and Manfredi, 2010; Barrett et al.,
2011; Martin, 2011; Cozzolino and Carrì, 2012; Vehviläinen
et al., 2014). In particular, increased cytosolic Ca2+ transients
and significantly reduced mitochondrial Ca2+ uptake have been
described in ALS mouse models (Jaiswal and Keller, 2009;
Coussee et al., 2011). The mitochondrial membrane poten-
tial, the driving force for mitochondrial Ca2+ uptake, has been
described to be depolarized, and/or Ca2+ induced depolariza-
tion was increased (Carrì et al., 1997; Damiano et al., 2006;
Jaiswal and Keller, 2009; Nguyen et al., 2009). By functional
comparison of MNs from the hypoglossal (hMN) and from
the oculomotor nucleus (oMN) in the most commonly uti-
lized mouse model of ALS that express a human disease causing
G93A SOD1 mutation (SOD1G93A mice), we recently identi-
fied a Ca2+ homeostasis deficit, selectively in highly vulnerable
hMNs at disease endstage (Fuchs et al., 2013). More precisely, in
response to elevated electrical activity, a reduced mitochondrial
Ca2+ uptake, and an enhanced Ca2+ extrusion across the plasma
membrane was observed in hMNs but not oMNs (Fuchs et al.,
2013).
The main assumed uptake route of Ca2+ into mitochondria is
the mitochondrial Ca2+ uniporter (mCU), driven by the mito-
chondrial membrane potential (Drago et al., 2011). It consists
of a pore-forming subunit, named mitochondrial Ca2+ uniporter
(MCU) and at least two regulatory subunits, mitochondrial Ca2+
uptake 1 (MICU1) and mitochondrial Ca2+ uniporter regula-
tor 1 (MCUR1) (Perocchi et al., 2010; Baughman et al., 2011;
de Stefani et al., 2011; Mallilankaraman et al., 2012a; Marchi
and Pinton, 2014). mCU has a relatively low Ca2+ sensitivity,
and probably achieves mitochondrial Ca2+ import mainly at
endoplasmic reticulum (ER) mitochondria microdomains, where
Ca2+ concentrations are high enough (Drago et al., 2011). The
mitochondrial uncoupling proteins UCP2 and UCP3 can also
contribute to the mitochondrial Ca2+ uptake machinery. First
reported to be a component of the uniporter itself (Trenker
et al., 2007), they were later supposed to operate indepen-
dently of other Ca2+ uptake pathways, particularly when Ca2+
is released from the ER (Waldeck-Weiermair et al., 2011). In
addition, the high Ca2+ affine leucine zipper EF-hand contain-
ing transmembrane protein 1 (Letm1) is supposed to func-
tion as mitochondrial Ca2+/H+ exchanger at the relatively low
cytosolic concentration increases across the plasma membrane
that follow Ca2+ depletion of the ER (store operated calcium
entry, SOCE) (Jiang et al., 2009; Waldeck-Weiermair et al., 2011;
Nowikovsky et al., 2012). Themitochondrial Na+/Ca2+exchanger
(MNCX) achieves Ca2+ efflux from mitochondria under phys-
iological conditions (Palty et al., 2010; de Marchi et al., 2014)
but might revert its operation mode when mitochondria undergo
pathological de- or hyperpolarization (Kim and Matsuoka, 2008;
Chinopoulos and Adam-Vizi, 2010). Apart from mitochondrial
Ca2+ uptake, the sarco-endoplasmic reticulum Ca2+ ATPases
(SERCA) are transporting Ca2+ into the ER, and thus provide
additional Ca2+ clearance capacity (Hovnanian, 2007; Chaudhari
et al., 2014; Hajnóczky et al., 2014). Furthermore, Ca2+ clear-
ance via the plasma membrane is present and mediated by
the plasma membrane Ca2+ ATPases (PMCA1-4) (Strehler,
2013) and the Na+/Ca2+ exchangers (NCX1-3) (Sharma and
O’Halloran, 2014). While NCX1-3 mediate extrusion of steep
Ca2+ increases after cell stimulation via the plasma membrane,
PMCA isoforms are regarded as “fine tuners” of cytosolic Ca2+
extrusion (Brini and Carafoli, 2011).
To molecularly define the described complex altered func-
tional Ca2+ clearance phenotype in hMNs of endstage SOD1G93A
mice (Fuchs et al., 2013), here we examined mRNA-levels of
all described potential mitochondrial (MCU/MICU1/MCUR1,
Letm1, UCP2/3, MNCX) and plasma-membrane (PMCA1-4,
NCX1-3) Ca2+ transport proteins in choline-acetyltransferase
(ChAT) positive hMNs of endstage SOD1G93A and wildtype (WT)
mice, by combining UV laser microdissection (UV-LMD) with
quantitative RT-PCR analysis. To assess if a possible cell-specific
transcriptional Ca2+ transporter dysregulation is associated with
an altered number of mitochondria/mitochondrial genomes in
SOD1G93A mice (Keeney and Bennett, 2010), we quantified mito-
chondrial genomic DNA in individual hMNs via quantification
of the mitochondrially encoded NADH dehydrogenase subunit 1
(ND1) gene (He et al., 2002; Bender et al., 2006; Krishnan et al.,
2007). As cDNA levels for ChAT as well as cDNA and genomic
DNA levels for ND1 were not altered in hMNs from SOD1G93A
mice compared to WT, we utilized these genes for normaliza-
tion of respective qPCR expression-data for plasma membrane
and mitochondrial Ca2+ transporters. With this stratified anal-
ysis, we detected a selective transcriptional up-regulation of
the mitochondrial MCU/MICU1 complex, similar as previously
described (Fuchs et al., 2013), as well as of Letm1, UCP2, and
the plasma membrane transporter NCX1. These findings point to
an activity-dependent increased need of Ca2+ clearance capacity
in hMNs of endstage SOD1G93A mice that is only partly met
by an increased expression of mitochondrial Ca2+ transporters.
Accordingly, Ca2+ extrusion via the plasma-membrane is elevated
in hMNs of endstage SOD1G93A mice—not only functionally
(Fuchs et al., 2013), but also at the molecular level, via ele-
vated NCX1 expression. Thus, pharmacological stimulation of
Ca2+ transporters might offer a novel neuroprotective strategy for
highly vulnerable MNs in ALS.
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MATERIALS AND METHODS
ETHICAL APPROVAL
All animal procedures were approved by Regierungspräsidium
Tübingen, Germany (AZ 35/9185.81-3 TV No. 1090, and O-
147), and conducted according to the guidelines of the German
Tierschutzgesetz.
MICE
For all experiments, male transgenic mice of the strain B6SJL-
TgN(SOD1-G93A) (Jackson Laboratory, Bar Harbor, US) and
wildtype (WT) littermates of the same genetic background were
used (Gurney et al., 1994). Mice were bred in Ulm in respective
in-house breeding facility and genotyped according to the proto-
col recommended by Jackson Laboratory. For analyses, SOD1G93A
mice between P115 and P145 were used after they were no longer
able to pass a paw grip endurance test (clinical score 4, referred to
as endstage) (Solomon et al., 2011). Data were derived from six
individual SOD1G93A and six respective age-matched WT mice.
TISSUE PREPARATION, UV LASER MICRODISSECTION (UV-LMD) AND
REVERSE TRANSCRIPTION (RT)
Carried out essentially as described (Fuchs et al., 2013;
Schlaudraff et al., 2014). Briefly, SOD1G93A and WT mice
were deeply anesthetized with isoflurane (Abbott, Wiesbaden,
Germany) and decapitated. Coronal tissue blocks containing
hypoglossal nuclei were separated. The blocks were mounted
on a specimen disk and immediately frozen by insertion into
the snap-freeze holder (−35◦C) of a cryostat (Leica CM 1850).
Twelve μm serial coronal brainstem sections (for exact location
see Figure 1A) were cut using a microtome blade (type R35,
Feather, Osaka, Japan), and mounted on 2mm PEN-membrane
slides (Microdissect, Herborn, Germany), fixed with an ascend-
ing ethanol series, stained with cresyl violet, dried and stored
at −80◦C. UV-LMD of individual hMNs was performed using
a Leica LMD7000 setup. 10 pools of 15 hMNs each were laser
microdissected from each endstage SOD1G93A and age-matched
WT mouse. After cell-lysis and reverse transcription (RT) with
random hexamer primers, cDNA was ethanol precipitated as
described (Liss, 2002), resolved in 17μl molecular biology grade
water and stored at −20◦C until PCR amplification. Note that
hMNs of SOD1G93A mice were about 5% larger than hMNs
of WT control mice, according to area-quantifications after
UV-LMD.
QUALITATIVE AND QUANTITATIVE PCR
Qualitative and quantitative PCR was carried out, essentially as
described (Gründemann et al., 2011; Dragicevic et al., 2014;
Schlaudraff et al., 2014). Quantitative PCR (qPCR) was car-
ried out using TaqMan assays and a GeneAmp 7900HTqPCR
cycler (Applied Biosystems, Darmstadt, Germany). All qPCR
assay details and assay-specific standard curve parameters are
given in Table 1. Standard curves were generated using serial dilu-
tions of cDNA (stock concentration: 750 ng/μl, RNA integrity
number (RIN): 9.8; derived from brainstem mRNA of an age-
matched C57Bl/6 mouse). Five μl of standard cDNA or of the
purified hMN cDNA was used as a template for each qPCR in
a final volume of 20μl, using QuantiTect Probe PCR Master Mix
(Qiagen, Hilden, Germany), 1μl TaqMan assay, and the following
cycling conditions: 60◦C 2min, 95◦C 15min, (94◦C 15 s, 60◦C
1min) 50 cycles.
To test for absence of contaminations in harvested hMN pools,
5μl of purified hMN cDNA was subjected to either multiplex-
nested PCR for qualitative (essentially as described, Dragicevic
et al., 2014) or to qPCR for quantitative analysis of marker gene
expression: We chose choline-acetyltransferase (ChAT) as marker
for motor neurons, L-glutamate decarboxylase (GAD65/67) as
marker for GABAergic cells, and glial fibrillary acidic protein
(GFAP) as marker for astroglia cells. In addition, we used NADH
dehydrogenase subunit 1 (ND1) as marker for mitochondrial
genomic DNA copies. Only ChAT positive and GAD65/67 negative
pools were further processed for Ca2+ transporter mRNA quan-
tification. Please note that we detected in pools (∼50–100%) as
well as in individual hMN (100%) from SOD1G93A but not from
WT mice (0 and 11% respectively) consistently robust GFAP sig-
nals (compare Figure 2A and Table 2A). As GFAP positive and
GFAP negative hMN pools from SOD1G93A showed however no
significant differences inMCU/MICU1Ca2+ transporters expres-
sion levels, GFAP positive hMN pools were included into the
analysis. Figure 1 illustrates the UV-LMD and RT-PCR workflow.
DETERMINATION OF MITOCHONDRIAL GENOME COPY NUMBER
For quantification of mitochondrial genome copy number, single
hMNs were laser microdissected and DNA isolation was per-
formed with the QiaAmp DNA Micro Kit (Qiagen) according
to the manufacturer protocol with the following adaptations:
0.1μg/μl polyA carrier-RNA (included in kit) was added to each
reaction, and all mixing steps were performed by pipetting with
cell saver tips (Kisker, Steinfurt, Germany) to minimize sheer-
ing stress. DNA was eluted in 30μl of molecular biology grade
water and stored at 4◦C until PCR amplification. For determina-
tion of mitochondrial DNA copy numbers, the mitochondrially
coded ND1 gene was quantified, that is almost never affected by
genomic deletion (He et al., 2002; Bender et al., 2006; Krishnan
et al., 2007). Five μl of the eluted genomic DNA was used in a
20μl reaction with QuantiTect Probe PCR Master Mix (Applied
Biosystems), 1μl ND1 TaqMan Primer Probe Mix, and 4μl H2O
for qPCR amplification in duplicate reactions in a GeneAmp
7900HT using the following cycling conditions: 60◦C 2min, 95◦C
15min, (94◦C 15 s, 60◦C 1min) 50 cycles. ND1 qPCR assay
details, and assay-specific standard curve parameters are given in
Table 1.
DATA ANALYSIS
Data analysis, graphical representations, correlation and lin-
ear regression analysis were performed with SDS2.3 software
(Applied Biosystems) and GraphPad Prism 6 (GraphPad Software
Inc., San Diego, US). The cDNA amount per neuron in relation
to the utilized standard was calculated as described (Gründemann
et al., 2011; Schlaudraff et al., 2014) according to:
cDNA amount per cell = S
[(Ct−Yintercept)slope]
Nocells • cDNA fraction
With S = serial dilution factor of the standard curve (i.e., 10),
Nocells = number of harvested neurons per UV-LMD sample (i.e.,
15), cDNA fraction = fraction of the UV-LMD cDNA-reaction
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FIGURE 1 | Scheme of UV-LMD and RT-qPCR protocol for quantitative
expression analysis of Ca2+ transporters in individual hypoglossal
motor neurons from endstage SOD1G93A and WT mice.
(A) Nissl-stained sagittal (left) adult mouse brain section. The black bar
indicates the zone (6–7mm posterior to the Bregma) within the brainstem,
where coronal sections (right) containing hypoglossal motor neurons
(hMNs) (black box) were cut for UV-LMD. Scale bars: 1mm. Pictures taken
from Paxinos and Franklin (2001). (B) Upper: Overview of a WT (left) and
endstage SOD1G93A mouse (right) coronal brainstem section after UV-LMD
of 15 individual hMNs each. Scale bars: 250μm. Inserts: photograph of the
reaction tube cap for inspection of proper collection of all 15 neurons after
UV-LMD, prior to cell lysis and reverse transcription (RT). Scale bars:
500μm. Lower: individual hMNs before and after UV-LMD. Scale bars:
10μm. (C) Workflow after UV-LMD. Left: genomic ND1 DNA-copy number
of single hMNs was determined via qPCR with using genomic DNA as
template, after genomic DNA isolation. ChAT and GFAP cDNA levels were
determined for single hMNs after cell-lysis via individual RT-qPCR reactions
with 50% of single cell cDNA each as templates. Right: For quantification
of Ca2+ transporter expression-levels, cDNA derived from pools of 15
hMNs each were splitted, and 1/3 was used for marker gene expression
profiling (either multiplex-nested PCR for ChAT, GFAP, and GAD65/67, or
alternatively individual qPCRs for ChAT, GFAP, and ND1), and 2/3 was used
for RT-qPCRs for quantification of Ca2+ transporter mRNA levels. For
details, please see methods.
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Table 1 | Mouse TaqMan quantitative PCR assay information.
Standard curve data
Assay ID Target gene reporter-context
sequence-quencher (primer sequences)
Genbank accession
no. (NCBI)
Ampl.
Length
[bp]
Exon
spanning
Threshold Y-Intercept Slope R2 n
Mm01168774_m1
MCU (Ccdc109a)
FAM-CACCAAAGAGAGACCTCCTAAGCCA-NFQ NM_001033259.3 92 4–5 0.6 45.77 ± 0.13 −3.43 ± 0.02 0.99 ± 0.00 8
Mm01173692_m1
MICU1 (Cbara1)
FAM-AGACAGAAAAGTGATGGAGTATGAG-NFQ NM_144822.2 67 3–4 0.6 44.73 ± 0.16 −3.39 ± 0.05 0.99 ± 0.00 8
Mm01351581_m1
MCUR1 (Ccdc90a)
FAM-AAAGCAACAAGTGATGGATGAAGTG-NFQ NM_001081059.3 98 5–6 0.6 46.13 ± 0.18 −3.14 ± 0.00 0.99 ± 0.01 2
Mm00522265_m1
Letm1
FAM-GCCAGCTGAAACAGTGGCTGGACTT-NFQ NM_019694.1 74 7–8 0.6 44.30 ± 0.44 −3.31 ± 0.11 1.00 ± 0.00 3
Mm01197102_m1
mNCX (Slc24a6)* NM_133221.2,
61 9–10/10–11 0.6 49.70 ± 0.71 −3.68 ± 0.17 0.98 ± 0.01 3FAM-TAGTCAAGTTGCCTGTGGAGTTCTT-NFQ NM_001177594.1,
NM_001177595.1
Mm01274107_g1
UCP2
FAM-GGTCCGGCTGCAGATCCAAGGGGAG-NFQ NM_011671.4 82 3–4 0.6 44.72 ± 0.18 −3.33 ± 0.06 0.99 ± 0.00 4
Mm00494077_m1
UCP3
FAM-GTCTCACCTGTTTACTGACAACTTC-NFQ NM_009464.3 69 5–6 0.6 48.62 ± 0.48 −3.33 ± 0.11 0.98 ± 0.01 5
Mm01245805_m1
PMCA1 (Atp2b1)
FAM-GGGGACCTTACTCTGGGGCCAGCTT-NFQ NM_026482.2 77 19–20 0.6 44.85 ± 0.32 −3.33 ± 0.09 0.99 ± 0.01 3
Mm00437640_m1
PMCA2 (Atp2b2)* NM_001036684.2,
79 7–8 0.6 42.32 ± 0.19 −3.29 ± 0.04 0.99 ± 0.00 4
FAM-ATAGGCAAGGCGGGCCTGGTGATGT-NFQ NM_009723.3
Mm00623641_m1
PMCA3 (Atp2b3)
FAM-AGACAAGAAAGGCAAGCAGCAGGAT-NFQ NM_177236.3 71 6–7 0.6 43.94 ± 0.31 −3.30 ± 0.08 1.00 ± 0.00 3
Mm01285597_m1
PMCA4 (Atp2b4)* NM_213616.3,
86 1–2 0.6 46.86 ± 0.25 −3.23 ± 0.05 0.99 ± 0.01 3
FAM-TGAAAACCTCCCCTATAGAAGGTCT-NFQ NM_001167949.1
Mm01232255_m1
NCX1 (Slc8a1)* NM_001112798.1,
65 7–8/9–10 0.6 45.60 ± 0.38 −3.38 ± 0.06 0.99 ± 0.00 3
FAM-ACTGTCAGCGCTGGGGAAGATGACG-NFQ NM_011406.2
Mm00455836_m1
NCX2 (Slc8a2)
FAM-AGGTGTAGTCCAGGTGTGGGAGGCA-NFQ NM_148946.2 100 2–3 0.6 46.75 ± 0.24 −3.26 ± 0.08 0.98 ± 0.02 3
Mm00475520_m1
NCX3 (Slc8a3)* NM_080440.3,
71 5-6/6–7 0.6 46.14 ± 0.53 −3.28 ± 0.13 0.99 ± 0.00 3
FAM-CATCACTGTTAGTGCAGGAGGGGAT-NFQ NM_001167920.1
Mm01221882_m1
ChAT
FAM-TAGCTGTGAGGAGGTGCTGGACTTA-NFQ NM_009891.2 67 3–4 0.8 46.13 ± 0.64 −3.04 ± 0.10 0.99 ± 0.00 3
Mm01253033_m1
GFAP* NM_001131020.1,
75 6–7 0.8 42.41 ± 0.10 −3.29 ± 0.04 0.99 ± 0.00 3
FAM-AGAAAACCGCATCACCATTCCTGTA-NFQ NM_010277.3
Mm04225274_s1
ND1
FAM-ACAACCATTTGCAGACGCCATAAAA-NFQ NC_005089_ND1.0 81 – 1.0 35.60 ± 0.56 −3.34 ± 0.03 1.00 ± 0.00 3
Threshold, slope and y-intercept values were determined with using serial dilutions of cDNA derived from mouse brainstem tissue as qPCR templates (for details,
please see methods). (*) Primers did detect but not discriminate between described splice variants.
sample used as template in the individual qPCR reactions (pools
of 15 hMNs: 5/17 for Ca2+ transporters, and 1/9 for marker
genes ChAT, GFAP, and ND1; single hMN: 1/2 for marker genes
ChAT and GFAP, and 1/6 for genomic ND1). The Yintercept unit-
magnitude corresponds to the respective standard utilized (i.e.,
pg equivalents of standard cDNA, derived from brainstem tis-
sue mRNA). Single cell cDNA amounts were calculated with a
Yintercept of 42 for all Ca2+ transporter genes, and with Yintercept
from respective standard curves for ChAT, GFAP and ND1.
Relative expression data are given as mean ± s.e.m., without
and with normalization to ND1 and ChAT DNA/cDNA levels,
respectively. Normalization was carried out by dividing respective
Ca2+ transporter expression values to respective relative ChAT
or ND1 expression values (relative to the WT mean values for
ChAT and ND1), for each individual hMN pool. For statistical
comparison Mann-Whitney-U-Tests were used. Significant dif-
ferences are indicated by asterisks (∗p < 0.05, ∗∗p < 0.01, and
∗∗∗p < 0.001).
RESULTS
To analyze expression levels of mitochondrial as well as plasma
membrane Ca2+ transporters in individual hMNs from WT and
endstage SOD1G93A mice with best possible stratification, we
further optimized our established single cell UV-LMD RT-qPCR
protocol (Gründemann et al., 2011; Fuchs et al., 2013; Schlaudraff
et al., 2014). Figure 1 summarizes the general work flow.
For cell-specific normalization and stratification of mito-
chondrial Ca2+ transporter mRNA expression-levels, we uti-
lized the NADH dehydrogenase ND1 gene, that is encoded by
mitochondrial genomic DNA, and is almost never affected by
genomic DNA-degradation (He et al., 2002; Bender et al., 2006).
Quantifying ND1 DNA copies in parallel with mitochondrial
Ca2+ transporter mRNAs in individual hMNs allows the nor-
malization of mitochondrial Ca2+ transporter expression levels
to the number of mitochondria/mitochondrial genomes in the
respective analyzed hMN pools. To probe if the number of
mitochondrial genomes is altered in individual hMNs from WT
and SOD1G93A mice, we first quantified ND1 genomic DNA
copy numbers after isolation of genomic DNA from individual
hMNs. We detected no significant difference in ND1 genomic
DNA levels in individual hMNs from WT and SOD1G93A mice
(Figure 2A and Table 2A). To probe if this is also the case, when
analyzing (intronless) genomic ND1 levels without a distinct
genomic DNA isolation step by using our established UV-LMD
RT-qPCR protocol (a prerequisite for using this gene and this
approach for RT-qPCR data normalization), we quantified ND1
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FIGURE 2 | Evaluation of ND1 and ChAT expression, used for
normalization of cell-specific hypoglossal motor neurons qPCR data.
(A) qPCR data for mitochondrially coded NADH dehydrogenase ND1,
using genomic DNA from individual hMNs as templates, indicate similar
numbers of mitochondrial genomic DNA molecules in hMNs from WT
and from endstage SOD1G93A mice. Note that combined mitochondrial
genomic DNA and cDNA levels for ND1, determined via RT-qPCR of
pools of 15 hMNs each, are also not different between WT and
SOD1G93A mice, a prerequisite for using ND1 DNA-levels for
normalization of respective mitochondrial Ca2+ transporter RT-qPCR
results. (B) RT-qPCR data for choline-acetyltransferase (ChAT), derived
either from single hMNs or from pools of 15 hMNs each, are similar in
WT and SOD1G93A mice, a prerequisite for using ChAT cDNA-levels for
normalization of respective plasma membrane Ca2+ transporter RT-qPCR
results. (C) WT and SOD1G93A coronal brainstem section after UV-LMD
of 15 individual hMNs and agarose gel products of multiplex-nested
RT-PCR of the marker genes ChAT, GFAP (glial fibrillary acidic protein),
and GAD65/67(L-glutamate decarboxylase). Note that most WT pools (or
individual hMNs) were GFAP-negative while GFAP was robustly detected
in ∼50% of SOD1G93A pools (or via qPCR in 100% of individual hMNs or
pools from SOD1G93A, compare Table 2A). Scale bars: 250μm.
DNA levels (genomic DNA + cDNA) in respective pools of 15
hMNs from WT and SOD1G93A mice. Again, we detected no dif-
ference between hMNs from WT and SOD1G93A mice, but as
expected, about 4-fold higher ND1 DNA levels (genomic DNA
+ cDNA) per cell (WT: 4.28; SOD1G93A: 4.30) (Figure 2A and
Table 2A).
For normalization and stratification of plasma membrane
Ca2+ transporter expression levels, we utilized the cytoplas-
mic key enzyme for acetylcholine synthesis, the choline-
acetyltransferase (ChAT). Again, as a prerequisite for using ChAT
for cell-specific normalization of hMN expression data, we deter-
mined ChAT mRNA-levels of individual hMNs as well as of
pools of hMNs in WT and endstage SOD1G93A mice. Similar,
as for ND1, we detected no difference in ChAT mRNA-levels in
single or pooled individual hMNs from WT and SOD1G93A mice
(Figure 2B and Table 2A). However, as expected, we detected a
strong correlation of ChAT mRNA-levels with individual hMN
cell sizes (WT: R2 = 0.45; p < 0.001; n = 50; SOD1G93A: R2 =
0.48; p < 0.001; n = 49), further indicating the suitability of
ChAT for normalization of plasma membrane Ca2+ transporter
expression data from individual hMNs.
To ensure homogeneity of laser microdissected hMN pools,
we analyzed for all hMN cDNA pools from WT and end-
stage SOD1G93A mice (n = 32 and 55, respectively) a respective
marker-gene expression profile. We utilized either qualitative
RT-multiplex nested PCR for ChAT, the astroglia-marker GFAP
(glial fibrilaric acidic protein) and the GABAergic neuron mark-
ers GAD65 and GAD67(L-glutamate-decarboxylase) (Figures 1C,
2C), or qPCR for ChAT and GFAP (Figure 1C and Table 2A).
Only ChAT positive and GAD65/67 negative hMN pools were
further analyzed. All ChAT positive hMN pools from WT or
SOD1G93A mice were negative for GAD65/67. However, as illus-
trated in Figure 2C, while WT pools showed no signal for GFAP,
we obtained positive GFAP RT-PCR signals in about 50% of
multiplex-nested PCRs of hMN cDNA pools from SOD1G93A
mice. To further address this unexpected finding, we quanti-
fied GFAP expression levels in pools of 15 hMNs as well as in
individual hMN of WT and SOD1G93A mice after UV-LMD.
Again, we almost never detected any robust signal for GFAP
in individual WT hMNs (n = 1 of 9 neurons), but in all 9
tested individual hMNs from SOD1G93A mice, and in 100%
(n = 50) of hMN pools (GFAP qPCR expression levels are given
in Table 2A). Given these results, it is very unlikely that GFAP
positive hMNs, selectively in SOD1G93A mice are caused arti-
ficially due to technical issues. We next compared MCU and
MICU1 mRNA-levels between GFAP positive and GFAP neg-
ative hMN pools of SOD1G93A mice, and detected no signifi-
cant difference (SOD1G93A, relative expression; MCU: GFAP pos.
1.71 ± 0.19, n = 16; GFAP neg. 1.65 ± 0.16, n = 23; p = 0.96;
MICU1: GFAP pos. 1.98 ± 0.22, n = 16; GFAP neg. 1.78 ±
0.15, n = 23; p = 0.51). Thus, we did not exclude GFAP posi-
tive hMN pools from further PCR analysis of Ca2+ transporter
expression.
Next, via RT-qPCR, we analyzed qualitative mRNA expres-
sion of the main described potential mitochondrial and
plasma membrane Ca2+ transporters (Figure 3A) in pools of
15 hMNs from WT and SOD1G93A mice. As illustrated in
Figure 3B, mRNAs for all tested mitochondrial Ca2+ transporters
(MCU/MICU1/MCUR1, Letm1, UCP2, MNCX) but UCP3, and
for all plasma membrane Ca2+ transporters (PMCA1-4, NCX1,
NCX3) but NCX2, were detected in ChAT and ND1 posi-
tive hMNs (n = 3 pools of 15 neurons each) from WT and
SOD1G93A mice. Accordingly, we quantified mRNA-levels for all
these mitochondrial and plasma membrane Ca2+ transporters
via qPCR in hMNs from WT and endstage SOD1G93A mice.
Results are given in Figure 4 and Table 2B. Without cell-specific
normalization, we detected significantly higher mRNA levels of
Frontiers in Cellular Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 353 | 6
Mühling et al. Calcium-transporter expression in SOD1 ALS-mice
only MICU1 and UCP2 in hMNs from SOD1G93A mice (each
about 1.7-fold higher compared to WT; Figure 4A left and
Table 2B). All other Ca2+ transporter mRNA-levels were not
significantly altered (although trends were observed in partic-
ular for MCU and Letm1, compare Figure 4A and Table 2B).
Accordingly, cell-specific normalization of hMN qPCR data for
mitochondrial Ca2+ transporters to mitochondrially coded ND1
DNA-levels (and thus to respective hMN mitochondrial genome
numbers) revealed significantly higher mRNA levels of not only
MICU1 and UCP2, but also of MCU and Letm1 in hMNs
from SOD1G93A mice (each about 1.8-fold higher compared
to WT), while levels of MCUR1 and MNCX were not altered
(Figure 4B left and Table 2B). In addition, by cell-specific nor-
malization of hMN qPCR data for all analyzed plasma mem-
brane Ca2+ transporters to relative ChAT levels (and thus to
respective hMN cell-sizes), we detected about 1.7-fold higher
mRNA-levels, selectively of NCX1 in hMNs from SOD1G93A mice
compared to WT (Figure 4B right and Table 2B). All other tested
plasma membrane Ca2+ transporters (PMCA1-4 and NCX3)
were not altered in hMNs from SOD1G93A mice compared to
those of WT.
In summary (Figure 4C), we detected at the mRNA-level a
concerted up-regulation of three distinct putative mitochon-
drial Ca2+ transporters, MCU/MICU1, Letm1 and UCP2, in
individual hMNs from endstage SOD1G93A mice compared
to WT, likely causing altered Ca2+ uptake of diseased mito-
chondria in hMN from SOD1G93A mice. The elevated expres-
sion of the plasma membrane Ca2+ transporter NCX1 pro-
vides a molecular explanation for the described functionally
enhanced activity dependent intracellular Ca2+ extrusion via the
plasma membrane in hMNs from SOD1G93A mice (Fuchs et al.,
2013).
FIGURE 3 | Qualitative expression profiling of putative mitochondrial
and plasma membrane Ca2+ transporters in individual hypoglossal
motor neurons from WT and endstage SOD1G93A mice. (A) Illustration of
proteins for main putative mitochondrial (MCU/MICU1/MICUR1, Letm1,
UCP2/3, MNCX), plasma membrane (PMCA1-4, NCX1-3) and ER (SERCA)
Ca2+ transporters in cholinergic (ChAT) hMNs. For details and abbreviations,
please see text. (B) Upper: Agarose gel (2%) electrophoresis of RT-qPCR
products indicates that all putative mitochondrial and plasma membrane Ca2+
transporters, as well as ChAT and ND1, are expressed in cDNA, derived from
mouse brainstem tissue (positive control). Lower: Agarose gel
electrophoresis of RT-qPCR products shows that all putative mitochondrial
and plasma membrane Ca2+ transporters, but UCP3 and NCX2, are
expressed in ChAT and ND1 positive hMNs from WT mice (as well as from
SOD1G93A mice, not shown) (bp: base pairs, DNA ladder).
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FIGURE 4 | Elevated mRNA-levels of distinct Ca2+ transporters in
individual hypoglossal motor neurons from SOD1G93A mice
compared to WT. (A) Cell-specific RT-qPCR data for mitochondrial and
plasma membrane Ca2+ transporters, derived from pools of 15 hMNs
each from SOD1G93A mice and WT. Data are given as [pg/cell] in
respect to a cDNA standard curve, generated from WT mouse
brainstem tissue. (B) Data from (A), normalized to mitochondrially
coded ND1 DNA-levels for mitochondrial Ca2+ transporters, and to ChAT
cDNA levels for plasma membrane Ca2+ transporters. Significant
differences according to Mann-Whitney-U-Tests are marked with (∗), as
defined in methods section. Note that data in (A,B) for the respective
genes refer to two different axes, as indicated by the dashed line.
(C) Right: Overview of concerted elevated Ca2+ transporter expression
in individual hMN from SOD1G93A mice compared to WT (marked in
red: MCU/MICU1, Letm1, UCP2, and NCX1). Left: These findings can
provide a molecular basis for the recently described, selective
functional, activity-dependent Ca2+ homeostasis deficit in hMN from
endstage SOD1G93A mice. Insert shows stimulation protocol and
resulting electrophysiological recordings (scale bar: 1 s), combined with
calcium imaging (for details please see text and Fuchs et al., 2013).
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DISCUSSION
Here we provide a cell-specific quantitative analysis of mitochon-
drial and plasma membrane Ca2+ transporter mRNA expression
in highly vulnerable cholinergic hypoglossal motor neurons from
SOD1G93A transgenic mice compared to WT. We identified a
selective up-regulation of the mitochondrial Ca2+ transporters
MCU/MICU1, Letm1 and UCP2 as well as of the plasma
membrane Na+/Ca2+ exchanger NCX1 in remaining hMNs in
endstage SOD1G93A mice, while cDNA and genomic DNA levels
for the mitochondrially coded ND1 gene, as well as cDNA levels
for ChAT, the key enzyme for acetylcholine-synthesis, were not
altered.
SOD1G93A transgenic mice are still the most widely used and
most extensively characterized mouse-model for ALS (Vinsant
et al., 2013a,b). These mice express a high copy number of the
human G93A mutant SOD1, and recapitulate many key features
of the human ALS phenotype, like adult disease onset, selective
motor neuron degeneration and axonal loss (Gurney et al., 1994;
Chiu et al., 1995; Fuchs et al., 2010). The limited clinical efficacy
of compounds tested on SOD1mice (Vucic et al., 2014), as well as
the notion that SOD1mutations account only for a small number
(∼2%) of sporadic ALS cases (Renton et al., 2013) prompted the
generation of new rodent ALS-models, like mice with mutated or
overexpressed TDP-43 or fused in sarcoma (FUS) (Da Cruz and
Cleveland, 2011; Van Den Bosch, 2011; Wegorzewska and Baloh,
2011;McGoldrick et al., 2013). However, given our previous func-
tional analysis of activity dependent Ca2+ homeostasis in hMNs
from SOD1G93A mice (Fuchs et al., 2013) and the fact that none
of the recently generated models was shown to recapitulate most
aspects of human ALS as convincing as the SOD1 mutant mouse,
we continued to focus on the analysis of SOD1G93A mice in this
complementary study.
Although mitochondrial dysfunction is present in MNs in
human ALS as well as in SOD1G93A mice (Barrett et al., 2011;
Martin, 2011), and macroscopic and functional alterations of
mitochondria have been characterized extensively (Kawamata
andManfredi, 2010; Cozzolino and Carrì, 2012; Vehviläinen et al.,
2014), the number of mitochondria/mitochondrial genomes in
highly vulnerable MNs to our knowledge has not yet been
addressed. Our cell-specific ND1 data (Figure 2A) argue against
significant changes in number of mitochondria or mitochon-
drial genomes (at least in the cell soma) in hMNs from endstage
SOD1G93A mice, compared to WT. In accordance with our find-
ings, ND2 genomic DNA levels in human postmortem spinal
cord motor neurons of ALS patients were also not altered com-
pared to controls, whereasmitochondrial genomicDNA-levels for
mitochondrially coded cytochrome oxidase and ND4 were sig-
nificantly lower in ALS (Keeney and Bennett, 2010)—probably
due to mitochondrial DNA deletions that occur preferentially in
the ND4 gene (He et al., 2002). These deletions or mutations are
likely to occur more frequently in ALS, as DNA repair enzymes in
mitochondria have been shown to be impaired (Murakami et al.,
2007).
In addition, our cell-specific data identified mitochondri-
ally coded ND1 as a well-suited gene for normalization and
further stratification of RT-qPCR data from hMNs. This is
particularly useful when analyzing cell-specific expression-levels
of targets with gene-products located in mitochondria
(like MCU/MICU1/MICUR1, Letm1, UCP2, and MNCX).
Furthermore, we identified ChAT as a well-suited gene for
normalization of RT-qPCR data for target-genes expressed in the
cytoplasm or in the plasma membranes of hMNs (like PMCA1-4
and NCX1/3). Our data show, that this cell- and transporter-
class-specific normalization approach allows stratification of
single cell hMN expression data, and thus reduces the number of
neurons or neuronal pools that need to be analyzed for detection
of significant differences (compare Figures 4A,B, Table 2B and
Fuchs et al., 2013); MCU here: n = 8 and 8; in Fuchs et al.
without normalization n = 21 and 39 for WT and SOD1G93A
hMN pools, respectively).
GFAP CO-EXPRESSION IN ChAT-POSITIVE hMNs SELECTIVELY FROM
SOD1G93A BUT NOT FROMWTMICE?
Surprisingly, with multiplex-nested PCR, as well as with more
sensitive qPCR, we detected GFAP co-expression in about 50 or
100% respectively, of analyzed ChAT positive hMN cDNA pools
from SOD1G93A mice but not in WT (Figure 2B and Table 2A).
How to interpret these findings? As we can exclude general
technical issues (i.e., contaminations), we provide two explana-
tions for the detected GFAP signals selectively in hMNs from
SOD1G93A but not WT mice. Either SOD1G93A hMNs might de-
differentiate or reprogram their neuronal phenotype due to the
disease process, as described for other cell types (Sarthy et al.,
1991; Hol et al., 2003; Arendt, 2008; Puri and Hebrok, 2012;
Qiang et al., 2013; Gao et al., 2014), and due to this process
co-express GFAP. Or alternatively, the well-described reactive
atsroglia cell activation and proliferation, present in ALS and
other neurodegenerative diseases (Guan et al., 2007; Chen et al.,
2012; Parpura et al., 2012; Forsberg et al., 2011; Bi et al., 2013),
might change the morphological astroglia—neuron interaction,
and thus, dendrites of astroglial cells might reside more closely to
hMNs from SOD1G93A compared to WT, and might have been
partly laser microdissected together with the hMN cell bodies.
However, it is important to note that we gained no morpho-
logical evidence for this latter GFAP contamination explanation
in our UV-LMD samples from SOD1G93A brains. Furthermore,
we never detected respective GFAP co-expression in individual
dopamine neurons from, e.g., Parkinson’s disease brains, where
a respective reactive gliosis also has been described (’Episcopo
et al., 2013), or from respective Parkinson’s disease mouse mod-
els, in over 15 years of UV-LMD RT-qPCR analysis of individual
dopamine neurons (Ramirez et al., 2006; Gründemann et al.,
2008, 2011; Schiemann et al., 2012; Schlaudraff et al., 2014). Thus,
while we can rule out general methodological issues, we cannot
for sure conclude that the detected GFAP signal of hMNs selec-
tively from SOD1G93A but not fromWTmice is genuinely derived
from hMNs, and further immunohistological studies are neces-
sary to address this point and its possible implication for ALS.
However, this surprising finding further highlights the emerging
crucial role of astroglia cells in ALS and its animal models (Valori
et al., 2014). Indeed mutant SOD1 expression has been shown to
greatly affect the astroglial functional phenotype, turning astro-
cytes into neurotoxic cells, more prone to cell death, and altering
their vital MN-supportive functions (Valori et al., 2014).
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Table 2 | Marker gene and Ca2+ transporter mRNA-levels in individual, laser microdissected hMNs from WT and endstage SOD1G93A mice.
A
Relative mRNA amount [pg/cell]
wildtype SOD1G93A
Mean ±s.e.m. n Mean ±s.e.m. n p
ChAT (15 hMNs) 15,196 1452 50 14,853 1156 49 0.80
ChAT (single hMN) 9411 1405 10 7743 2012 10 0.35
GFAP (15 hMNs) 1.85 0.50 50 80.38 8.46 50 <0.001***
GFAP (single hMNs) 0.49 0.49 10 87.62 15.77 10 <0.001***
ND1† (15 hMNs) 258.5 23.22 30 232.0 18.82 30 0.51
ND1# (single hMN) 60.32 3.64 28 53.91 3.73 29 0.23
B
(1) Relative mRNA amount [pg/cell] (2) Relative amounts, normalized to ND1 levels [pg/cell]
Wildtype SOD1G93A wildtype SOD1G93A
Mean ±s.e.m. n Mean ±s.e.m. n p Mean ±s.e.m. n Mean ±s.e.m. n p
MCU 13.17 2.98 8 23.88 4.00 10 0.08 13.57 2.98 8 25.29 4.41 10 0.04*
MICU1 41.18 8.02 10 68.90 3.80 8 0.03* 38.79 6.28 10 69.95 8.80 8 0.02*
MCUR1 4.90 1.03 9 5.24 0.90 10 0.70 4.69 0.70 9 6.13 0.83 10 0.39
LETM1 36.78 6.32 15 53.89 7.13 16 0.08 31.86 3.64 9 54.25 7.26 10 0.01*
UCP2 3.27 0.61 15 5.48 0.73 14 0.03* 3.79 0.74 10 6.85 0.82 9 0.01*
UCP3 – – 5 – – 5 – – – 5 – – 5 –
MNCX 4.33 1.42 10 4.22 0.77 10 0.47 3.83 0.74 10 4.41 0.60 10 0.39
(3) Relative amounts, normalized to ChAT levels [pg/cell]
PMCA1 84.42 12.52 10 76.55 19.11 10 0.39 87.15 5.32 8 98.53 11.90 8 0.43
PMCA2 197.30 46.89 9 126.0 41.11 9 0.31 178.4 20.07 7 140.2 20.20 7 0.46
PMCA3 75.60 17.34 10 61.33 12.16 10 0.57 78.76 10.82 6 85.28 14.58 6 0.68
PMCA4 12.08 2.88 16 8.58 1.54 16 0.58 23.56 7.45 6 18.69 3.66 6 0.68
NCX1 19.39 3.05 10 20.24 3.89 10 0.95 15.99 1.96 6 28.07 4.48 6 0.03*
NCX2 – – 5 – – 5 – – – 5 – – 5 –
NCX3 21.46 3.31 10 21.39 6.84 10 0.24 24.89 5.24 6 28.47 10.86 6 0.79
(A) RT-qPCR data for the marker-genes ChAT, GFAP, and ND1, derived from either pools of 15 hMNs, or from one individual hMN, given as pg/cell in respect to
cDNA standard curves, generated from WT mouse brainstem tissue. Note that ND1 DNA-levels for individual hMNs (#) were derived from isolated genomic DNA
(without RT), while ND1 DNA-levels from pools of 15 hMNs (†) were derived from cDNA + genomic DNA. Note that in contrast to WT, via qPCR, GFAP was robustly
detected in about 100% of ChAT positive hMNs of endstage SOD1G93A mice (compare Figure 2C). (B) RT-qPCR data for mitochondrial and plasma membrane Ca2+
transporters, derived from pools of 15 hMN each. Data are given (1) as [pg/cell] in respect to a cDNA standard curve, generated from WT mouse brainstem tissue,
and (2) normalized to mitochondrially coded ND1 DNA-levels for mitochondrial Ca2+ transporters, or (3) normalized to ChAT cDNA levels for plasma membrane Ca2+
transporters. Significant differences according to Mann-Whitney-U-Tests are marked in bold and with (*), as defined in methods section.
ELEVATED mRNA LEVELS OF THE MITOCHONDRIAL Ca2+
TRANSPORTERS MCU/MICU1, LETM1 AND UCP2 AND THE PLASMA
MEMBRANE Na+/Ca2+ EXCHANGER NCX1 IN hMNs OF SOD1G93A
MICE
The present study was motivated by our recent finding of an
activity-dependent Ca2+ clearance deficit selectively in individ-
ual hMNs, at the endstage of disease in SOD1G93A mice (Fuchs
et al., 2013). More precisely, by combining patch-clamp anal-
ysis with fura-2 calcium imaging and selective pharmacology
(e.g., the MCU-inhibitor RU-360) of individual, highly vul-
nerable hypoglossal and mostly resistant oculomotor MNs, we
identified a remodeling of activity-dependent, intracellular Ca2+
clearance, selectively in hMNs in SOD1G93A mice at disease
endstage, that was characterized by a reduction of mCU-mediated
mitochondrial Ca2+ uptake, and an enhanced Ca2+ extrusion
across the plasma membrane, under high-Ca2+ loading con-
ditions (Fuchs et al., 2013). Our preliminary molecular anal-
ysis pointed to a complex underlying mechanism, as mRNA-
levels of the mCU core components MCU and MICU1 were
about 1.7-fold higher in hMNs from SOD1G93A mice (Fuchs
et al., 2013). With an improved UV-LMD RT-qPCR proto-
col (Figures 1, 2), we could reproduce these findings in an
independent cohort of mice (Figures 4A,B; Table 1B). Increased
MCU/MICU1 expression might enforce metabolic coupling, as
mitochondrial Ca2+ activates, e.g., enzymes of the tricarboxylic
acid cycle (McCormack and Denton, 1990; Wiederkehr et al.,
2011). On the other hand, MICU1 does also act as gate-
keeper of mCU that sets a threshold for maximal Ca2+ uptake.
Thus, a MICU1 up-regulation provides a protective mecha-
nism against mitochondrial calcium overload due to increased
cytosolic Ca2+ levels (Mallilankaraman et al., 2012b), preventing
excessive ROS generation and apoptosis (de Stefani et al., 2011).
This mCU repressor-function of elevated MICU1 could explain
the described functionally reduced mitochondrial Ca2+ uptake,
while MICU1 and MCU mRNA levels are elevated. The finding
that mRNA-levels of another regulatory mCU subunit MCUR1
(Mallilankaraman et al., 2012a) were not altered in hMNs from
SOD1G93A mice, further supports the idea that the stoichiome-
try and thus general function of mCU might indeed be altered in
hMNs from SOD1G93A mice. Additional mCU components have
recently been identified (Marchi and Pinton, 2014), like EMRE
and MICU2, which regulate MCU/MICU1 activity (Ahuja and
Muallem, 2014; Kamer and Mootha, 2014; Kevin Foskett and
Madesh, 2014), that need to be analyzed in further studies.
In addition to elevated MCU/MICU1 levels, we detected sim-
ilarly elevated levels for Letm1 as well as for UCP2 mRNA in
hMNs from SOD1G93A mice, while UCP3 mRNA was neither
detected in hMNs from WT nor from transgenes (Figures 4A,B;
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Table 1B). Letm1 is regarded as a highly Ca2+ sensitive mito-
chondrial Ca2+/H+ exchanger, operating mainly at cytosolic
Ca2+ levels below 1μM (Jiang et al., 2009; Waldeck-Weiermair
et al., 2011). As significant mitochondrial Ca2+ uptake via the
mCU becomes apparent particularly at cytosolic Ca2+ con-
centrations not below 5–10μm (Rizzuto and Pozzan, 2006;
Marchi and Pinton, 2014), a concerted up-regulation of mCU
and Letm1 migth counteract pathophysiological activity depen-
dent, altered cytosolic Ca2+ levels in SOD1G93A mice, and
thereby promote hMN survival. This complex view is further
supported by the detected elevated levels of UCP2 in hMNs
from SOD1G93A mice. In addition to the proposed mediated
direct mitochondrial Ca2+ uptake, UCP2 acts as mitochondrial
uncoupling protein, and thus decreases the amount of reac-
tive oxygen species produced by a steep proton gradient of the
respiratory chain (Donadelli et al., 2014). This mild uncou-
pling has been shown to be neuroprotective in highly vulner-
able dopamine neurons in mouse models of Parkinson’s dis-
ease (Liss et al., 2005; Guzman et al., 2010). However, over-
expression of human UCP2 in SOD1G93A mice paradoxically
accelerated disease progression and further reduced mitochon-
drial Ca2+ uptake capacity (Peixoto et al., 2013). The authors
conclude, that in bio-energetically defective mitochondria of
SOD1G93A mice, UCP2 might have adverse effects, possibly
by enhancing sensitivity to Ca2+ induced depolarization of
mitochondria and/or interacting with other Ca2+ uptake path-
ways.
Mitochondrial Ca2+ uptake and Ca2+ transporter activity is
closely related to ER Ca2+ uptake, predominantly mediated by
SERCA (Hovnanian, 2007; Chaudhari et al., 2014; Hajnóczky
et al., 2014). We did however not analyze mRNA expression
levels of SERCA-isoforms, as our previous functional and phar-
macological (thapsigargin) analysis gave no hint for altered ER
Ca2+ uptake in hMNs of endstage SOD1G93A mice, but for
enhanced plasma membrane Ca2+extrusion (compare Figure 4C
and Fuchs et al., 2013). In accordance with this functional phe-
notype, we detected an about 1.7-fold higher mRNA-level of the
plasma membrane Na+/Ca2+ exchanger NCX1 in hMNs from
SOD1G93A mice, while NCX2 was not expressed, and NCX3 as
well as PMCX1-4 mRNA-levels were not altered (Figure 4 and
Table 2B). The lack of NCX2 mRNA detection in hMNs from
WT as well as from SOD1G93A mice is somewhat surprising,
since this isoform was attributed a key role in neuronal Ca2+
homeostasis (Brini and Carafoli, 2011). The low-affinity/high-
capacity Ca2+ transporter NCX is believed to mediate the bulk
of plasma membrane Ca2+ export after stimulation, rather than
the PMCAs (Brini and Carafoli, 2011; Sharma and O’Halloran,
2014). Moreover, NCXs are controlled by cytosolic concentra-
tions of Na+ and Ca2+ (Brini and Carafoli, 2011), thus the
observed increased functional plasma membrane Ca2+-extrusion
is likely caused by an enhanced NCX1 expression, accompa-
nied by an enhanced functional NCX transport capacity, due to
pathologically elevated cytosolic Ca2+ and a reduced mitochon-
drial Ca2+ uptake capacity in hMNs from endstage SOD1G93A
mice. Vice versa, overexpression of NCX1 has been shown to
reduce not only cytosolic but also mitochondrial Ca2+ transients,
providing an additional feedback loop to protect mitochondria
from an extensive Ca2+ overload (Brini et al., 2002). An up-
regulation of NCX1 in neurons has been demonstrated to be
neuroprotective in other pathologic conditions, e.g., ischemic
events (Pignataro et al., 2012). However, PMCAs are also stim-
ulated by Ca2+ via calmodulin or phosphorylation (Strehler,
2013; Lopreiato et al., 2014). As specific PMCA splice vari-
ants differ, e.g., in their affinity and reaction upon calmod-
ulin binding (Brini et al., 2013; Strehler, 2013), an patho-
logic shift in PMCA splice variants might also contribute to
enhanced plasma membrane Ca2+ extrusion in hMNs from
SOD1G93A mice. It is noteworthy in this context, that our PMCA
TaqMan assays are detecting but not discriminating distinct
PMCA splice variants. To date, functional studies of plasma
membrane Ca2+ transporters are hampered by lack of specific
pharmacology which makes it difficult to address the distinct
contributions of individual NCX- or PMCA-isoforms (Strehler,
2013).
In conclusion, this study provides novel molecular and cell-
specific insights into the complex nature of cytosolic Ca2+
dysregulation and mitochondrial dysfunction in highly vulner-
able hMNs in the most common ALS mouse model, the end-
stage SOD1G93A mice. The detected concerted up-regulation
of distinct mitochondrial and plasma membrane Ca2+ trans-
porters with different locations as well as transport kinetics
(mCU, Letm1, UCP2, NCX1) might serve as a complex com-
pensatory response to the disease trigger and to the altered
Ca2+ homeostasis, and protect hMNs in SOD1G93A mice from
mitochondrial Ca2+ overload and degeneration. However, as
we analyzed endstage SOD1G93A mice, where already about
30% of hMNs are lost (Haenggeli and Kato, 2002), we do
not know, if the molecular up-regulation of distinct Ca2+
transporters did indeed protect those remaining hMNs from
degeneration.
AUTHOR CONTRIBUTIONS
TM and JD carried out all experiments and performed data analy-
sis, TM, JD and BL designed the study and wrote the manuscript.
JHW and ACL bred and provided SOD1G93A and WT mice and
revised the manuscript.
ACKNOWLEDGMENTS
We thank Andrea Fuchs for initial training in preparation
of hypoglossal nuclei in SOD1G93A and WT mice, Andreas
Bender for advice concerning genomic ND1 quantification,
and Dietmar Thal and Bernhard Keller for general discus-
sion. We thank Stefanie Schulz, Desiree Spaich and Tanja
Wipp for excellent technical support. This work was sup-
ported by the BMBF (NGFN 01GS08134), by the DFG (SFB497
ans Li1745), the Austrian Science Fund (FWF SFB F4412),
and the Alfried Krupp prize (all to BL), as well as by the
German network for ALS research (MND-NET), the Charcot
Foundation for ALS Research and the virtual Helmholtz
Institute (to ACL and JHW). TM and JD were supported by
the MD and PhD programs for Experimental and Molecular
Medicine and the Research Training Group CEMMA (DFG) of
Ulm University.
Frontiers in Cellular Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 353 | 11
Mühling et al. Calcium-transporter expression in SOD1 ALS-mice
REFERENCES
Ahuja, M., and Muallem, S. (2014). The gatekeepers of mitochondrial
calcium influx: MICU1 and MICU2. EMBO Rep. 15, 205–206. doi:
10.1002/embr.201438446
Arendt, T. (2008). “Differentiation and de-differentiation—neuronal cell-cycle reg-
ulation during development and age-related neurodegenerative disorders,” in
Handbook of Neurochemistry and Molecular Neurobiology, eds A. Lajtha, J. R.
Perez-Polo, and S. Rossner (Boston, MA: Springer US), 157–213.
Barrett, E. F., Barrett, J. N., and David, G. (2011). Mitochondria in motor nerve ter-
minals: function in health and in mutant superoxide dismutase 1 mouse models
of familial ALS. J. Bioenerg. Biomembr. 43, 581–586. doi: 10.1007/s10863-011-
9392-1
Baughman, J. M., Perocchi, F., Girgis, H. S., Plovanich, M., Belcher-Timme, C. A.,
Sancak, Y., et al. (2011). Integrative genomics identifies MCU as an essential
component of the mitochondrial calcium uniporter. Nature 476, 341–345. doi:
10.1038/nature10234
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R.
H., et al. (2006). High levels of mitochondrial DNA deletions in substantia
nigra neurons in aging and Parkinson disease. Nat. Genet. 38, 515–517. doi:
10.1038/ng1769
Bi, F., Huang, C., Tong, J., Qiu, G., Huang, B., Wu, Q., et al. (2013). Reactive astro-
cytes secrete lcn2 to promote neuron death. Proc. Natl. Acad. Sci. U.S.A. 110,
4069–4074. doi: 10.1073/pnas.1218497110
Brini, M., Calì, T., Ottolini, D., and Carafoli, E. (2013). The plasma mem-
brane calcium pump in health and disease. FEBS J. 280, 5385–5397. doi:
10.1111/febs.12193
Brini, M., and Carafoli, E. (2011). The plasma membrane Ca2+ ATPase and the
plasma membrane sodium calcium exchanger cooperate in the regulation of
cell calcium. Cold Spring Harb. Perspect. Biol. 3:a004168. doi: 10.1101/cshper-
spect.a004168
Brini, M., Manni, S., and Carafoli, E. (2002). A study of the activity of the plasma
membrane Na/Ca exchanger in the cellular environment. Ann. N.Y. Acad. Sci.
976, 376–381. doi: 10.1111/j.1749-6632.2002.tb04764.x
Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A.,
Copeland, N. G., et al. (1997). ALS-linked SOD1 mutant G85R medi-
ates damage to astrocytes and promotes rapidly progressive disease with
SOD1-containing inclusions.Neuron 18, 327–338. doi: 10.1016/S0896-6273(00)
80272-X
Carrì, M. T., Ferri, A., Battistoni, A., Famhy, L., Gabbianelli, R., Poccia,
F., et al. (1997). Expression of a Cu,Zn superoxide dismutase typical
of familial amyotrophic lateral sclerosis induces mitochondrial alteration
and increase of cytosolic Ca2+ concentration in transfected neuroblas-
toma SH-SY5Y cells. FEBS Lett. 414, 365–368. doi: 10.1016/S0014-5793(97)
01051-X
Charcot, J., and Joffroy, A. (1869). Deux cas d’atrophie musculaire progressive
avec lésions de la substance grise et des faisceaux antéro-latéraux de la moelle
épiniére. Arch. Physiol. Neurol Path. 2, 744–750.
Chaudhari, N., Talwar, P., Parimisetty, A., Lefebvre d’Hellencourt, C., and Ravanan,
P. (2014). A molecular web: endoplasmic reticulum stress, inflammation, and
oxidative stress. Front. Cell. Neurosci. 8:213. doi: 10.3389/fncel.2014.00213
Chen, Y., Guan, Y., Liu, H., Wu, X., Yu, L., Wang, S., et al. (2012). Activation of
the Wnt/β-catenin signaling pathway is associated with glial proliferation in the
adult spinal cord of ALS transgenic mice. Biochem. Biophys. Res. Commun. 420,
397–403. doi: 10.1016/j.bbrc.2012.03.006
Chinopoulos, C., and Adam-Vizi, V. (2010). Mitochondrial Ca2+ sequestration
and precipitation revisited. FEBS J. 277, 3637–3651. doi: 10.1111/j.1742-
4658.2010.07755.x
Chiu, A. Y., Zhai, P., Dal Canto, M. C., Peters, T. M., Kwon, Y. W., Prattis, S. M.,
et al. (1995). Age-dependent penetrance of disease in a transgenic mouse model
of familial amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 6, 349–362. doi:
10.1006/mcne.1995.1027
Cleveland, D. W., and Rothstein, J. D. (2001). From Charcot to Lou Gehrig: deci-
phering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2, 806–819.
doi: 10.1038/35097565
Coussee, E., de Smet, P., Bogaert, E., Elens, I., van Damme, P., Willems, P.,
et al. (2011). G37R SOD1 mutant alters mitochondrial complex I activ-
ity, Ca2+ uptake and ATP production. Cell Calcium 49, 217–225. doi:
10.1016/j.ceca.2011.02.004
Cozzolino, M., and Carrì, M. T. (2012). Mitochondrial dysfunction in ALS. Prog.
Neurobiol. 97, 54–66. doi: 10.1016/j.pneurobio.2011.06.003
Da Cruz, S., and Cleveland, D. W. (2011). Understanding the role of TDP-43
and FUS/TLS in ALS and beyond. Curr. Opin. Neurobiol. 21, 904–919. doi:
10.1016/j.conb.2011.05.029
Damiano, M., Starkov, A. A., Petri, S., Kipiani, K., Kiaei, M., Mattiazzi, M.,
et al. (2006). Neural mitochondrial Ca2+ capacity impairment precedes the
onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice.
J. Neurochem. 96, 1349–1361. doi: 10.1111/j.1471-4159.2006.03619.x
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M.,
Rutherford, N. J., et al. (2011). Expanded GGGGCC hexanucleotide repeat in
noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.
Neuron 72, 245–256. doi: 10.1016/j.neuron.2011.09.011
de Marchi, U., Santo-Domingo, J., Castelbou, C., Sekler, I., Wiederkehr, A., and
Demaurex, N. (2014). NCLX protein, but not LETM1, mediates mitochon-
drial Ca2+ extrusion, thereby limiting Ca2+-induced NAD(P)H production
and modulating matrix redox state. J. Biol. Chem. 289, 20377–20385. doi:
10.1074/jbc.M113.540898
de Stefani, D., Raffaello, A., Teardo, E., Szabò, I., and Rizzuto, R. (2011). A
forty-kilodalton protein of the inner membrane is the mitochondrial calcium
uniporter. Nature 476, 336–340. doi: 10.1038/nature10230
Donadelli, M., Dando, I., Fiorini, C., and Palmieri, M. (2014). UCP2, a mitochon-
drial protein regulated at multiple levels. Cell. Mol. Life Sci. 71, 1171–1190. doi:
10.1007/s00018-013-1407-0
Dragicevic, E., Poetschke, C., Duda, J., Schlaudraff, F., Lammel, S., Schiemann,
J., et al. (2014). Cav1.3 channels control D2-autoreceptor responses via NCS-
1 in substantia nigra dopamine neurons. Brain 137(Pt 8), 2287–2302. doi:
10.1093/brain/awu131
Drago, I., Pizzo, P., and Pozzan, T. (2011). After half a century mitochondrial cal-
cium in- and efflux machineries reveal themselves. EMBO J. 30, 4119–4125. doi:
10.1038/emboj.2011.337
’Episcopo, F. L., Tirolo, C., Testa, N., Caniglia, S., Morale, M. C., and Marchetti,
B. (2013). Reactive astrocytes are key players in nigrostriatal dopaminergic
neurorepair in theMPTPmouse model of Parkinson’s disease: focus on endoge-
nous neurorestoration. Curr. Aging Sci. 6, 45–55. doi: 10.2174/18746098113060
10007
Ferraiuolo, L., Kirby, J., Grierson, A. J., Sendtner, M., and Shaw, P. J. (2011).
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis.
Nat. Rev. Neurol. 7, 616–630. doi: 10.1038/nrneurol.2011.152
Forsberg, K., Andersen, P. M., Marklund, S. L., and Brännström, T. (2011).
Glial nuclear aggregates of superoxide dismutase-1 are regularly present in
patients with amyotrophic lateral sclerosis. Acta Neuropathol. 121, 623–634. doi:
10.1007/s00401-011-0805-3
Fuchs, A., Kutterer, S., Mühling, T., Duda, J., Schütz, B., Liss, B., et al. (2013).
Selective mitochondrial Ca2+ uptake deficit in disease endstage vulnerable
motoneurons of the SOD1G93A mouse model of amyotrophic lateral sclerosis.
J. Physiol. (Lond.) 591(Pt 10), 2723–2745. doi: 10.1113/jphysiol.2012.247981
Fuchs, A., Ringer, C., Bilkei-Gorzo, A., Weihe, E., Roeper, J., and Schütz,
B. (2010). Downregulation of the potassium chloride cotransporter KCC2
in vulnerable motoneurons in the SOD1-G93A mouse model of amy-
otrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 69, 1057–1070. doi:
10.1097/NEN.0b013e3181f4dcef
Gao, T., McKenna, B., Li, C., Reichert, M., Nguyen, J., Singh, T., et al. (2014). Pdx1
maintains β cell identity and function by repressing an α cell program. Cell
Metab. 19, 259–271. doi: 10.1016/j.cmet.2013.12.002
Grosskreutz, J., Haastert, K., Dewil, M., van Damme, P., Callewaert, G., Robberecht,
W., et al. (2007). Role of mitochondria in kainate-induced fast Ca2+ tran-
sients in cultured spinal motor neurons. Cell Calcium 42, 59–69. doi:
10.1016/j.ceca.2006.11.010
Grosskreutz, J., Van Den Bosch, L., and Keller, B. U. (2010). Calcium dys-
regulation in amyotrophic lateral sclerosis. Cell Calcium 47, 165–174. doi:
10.1016/j.ceca.2009.12.002
Gründemann, J., Schlaudraff, F., Haeckel, O., and Liss, B. (2008). Elevated alpha-
synuclein mRNA levels in individual UV-laser-microdissected dopaminergic
substantia nigra neurons in idiopathic Parkinson’s disease. Nucleic Acids Res.
36, e38. doi: 10.1093/nar/gkn084
Gründemann, J., Schlaudraff, F., and Liss, B. (2011). UV-laser microdissection and
mRNA expression analysis of individual neurons from postmortem Parkinson’s
Frontiers in Cellular Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 353 | 12
Mühling et al. Calcium-transporter expression in SOD1 ALS-mice
disease brains.Methods Mol. Biol. 755, 363–374. doi: 10.1007/978-1-61779-163-
5_30
Guan, Y. J., Wang, X., Wang, H. Y., Kawagishi, K., Ryu, H., Huo, C. F., et al. (2007).
Increased stem cell proliferation in the spinal cord of adult amyotrophic lateral
sclerosis transgenic mice. J. Neurochem. 102, 1125–1138. doi: 10.1111/j.1471-
4159.2007.04610.x
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander,
D. D., et al. (1994). Motor neuron degeneration in mice that express a
human Cu,Zn superoxide dismutase mutation. Science 264, 1772–1775. doi:
10.1126/science.8209258
Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E.,
Schumacker, P. T., et al. (2010). Oxidant stress evoked by pacemaking in
dopaminergic neurons is attenuated by DJ-1. Nature 468, 696–700. doi:
10.1038/nature09536
Haenggeli, C., and Kato, A. C. (2002). Differential vulnerability of cranial motoneu-
rons in mouse models with motor neuron degeneration. Neurosci. Lett. 335,
39–43. doi: 10.1016/S0304-3940(02)01140-0
Haeusler, A. R., Donnelly, C. J., Periz, G., Simko, E. A. J., Shaw, P. G., Kim, M.-S.,
et al. (2014). C9orf72 nucleotide repeat structures initiate molecular cascades of
disease. Nature 507, 195–200. doi: 10.1038/nature13124
Hajnóczky, G., Booth, D., Csordás, G., Debattisti, V., Golenár, T., Naghdi, S., et al.
(2014). Reliance of ER-mitochondrial calcium signaling on mitochondrial EF-
hand Ca(2+) binding proteins: miros, MICUs, LETM1 and solute carriers. Curr.
Opin. Cell Biol. 29C, 133–141. doi: 10.1016/j.ceb.2014.06.002
Hardiman, O., van den Berg, L. H., and Kiernan, M. C. (2011). Clinical diagnosis
and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 7, 639–649.
doi: 10.1038/nrneurol.2011.153
He, L., Chinnery, P. F., Durham, S. E., Blakely, E. L., Wardell, T. M., Borthwick,
G. M., et al. (2002). Detection and quantification of mitochondrial DNA dele-
tions in individual cells by real-time PCR. Nucleic Acids Res. 30, e68. doi:
10.1093/nar/gnf067
Hol, E.M., Roelofs, R. F., Moraal, E., Sonnemans,M. A. F., Sluijs, J. A., Proper, E. A.,
et al. (2003). Neuronal expression of GFAP in patients with Alzheimer pathol-
ogy and identification of novel GFAP splice forms. Mol. Psychiatry 8, 786–796.
doi: 10.1038/sj.mp.4001379
Hovnanian, A. (2007). SERCA pumps and human diseases. Subcell. Biochem. 45,
337–363. doi: 10.1007/978-1-4020-6191-2_12
Ilieva, H., Polymenidou, M., and Cleveland, D. W. (2009). Non-cell autonomous
toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187,
761–772. doi: 10.1083/jcb.200908164
Jaiswal, M. K., and Keller, B. U. (2009). Cu/Zn superoxide dismutase typical for
familial amyotrophic lateral sclerosis increases the vulnerability of mitochon-
dria and perturbs Ca2+ homeostasis in SOD1G93A mice. Mol. Pharmacol. 75,
478–489. doi: 10.1124/mol.108.050831
Jiang, D., Zhao, L., and Clapham, D. E. (2009). Genome-wide RNAi screen identi-
fies Letm1 as a mitochondrial Ca2+/H+ antiporter. Science 326, 144–147. doi:
10.1126/science.1175145
Kamer, K. J., and Mootha, V. K. (2014). MICU1 and MICU2 play nonredundant
roles in the regulation of the mitochondrial calcium uniporter. EMBO Rep. 15,
299–307. doi: 10.1002/embr.201337946
Kanning, K. C., Kaplan, A., and Henderson, C. E. (2010). Motor neuron diver-
sity in development and disease. Annu. Rev. Neurosci. 33, 409–440. doi:
10.1146/annurev.neuro.051508.135722
Kaplan, A., Spiller, K. J., Towne, C., Kanning, K. C., Choe, G. T., Geber,
A., et al. (2014). Neuronal matrix metalloproteinase-9 is a determinant of
selective neurodegeneration. Neuron 81, 333–348. doi: 10.1016/j.neuron.2013.
12.009
Kawamata, H., and Manfredi, G. (2010). Mitochondrial dysfunction and intra-
cellular calcium dysregulation in ALS. Mech. Ageing Dev. 131, 517–526. doi:
10.1016/j.mad.2010.05.003
Keeney, P. M., and Bennett, J. P. (2010). ALS spinal neurons show varied and
reducedmtDNA gene copy numbers and increasedmtDNA gene deletions.Mol.
Neurodegener 5:21. doi: 10.1186/1750-1326-5-21
Kevin Foskett, J., and Madesh, M. (2014). Regulation of the mitochondrial Ca(2+)
uniporter by MICU1 and MICU2. Biochem. Biophys. Res. Commun. 449,
377–383. doi: 10.1016/j.bbrc.2014.04.146
Kim, B., and Matsuoka, S. (2008). Cytoplasmic Na+-dependent modulation
of mitochondrial Ca2+ via electrogenic mitochondrial Na+-Ca2+ exchange.
J. Physiol. 586, 1683–1697. doi: 10.1113/jphysiol.2007.148726
Krishnan, K. J., Bender, A., Taylor, R. W., and Turnbull, D. M. (2007). A multi-
plex real-time PCR method to detect and quantify mitochondrial DNA dele-
tions in individual cells. Anal. Biochem. 370, 127–129. doi: 10.1016/j.ab.2007.
06.024
Lee, E. B., Lee, V. M.-Y., and Trojanowski, J. Q. (2012). Gains or losses: molecu-
lar mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 13,
38–50. doi: 10.1038/nrn3121
Liss, B. (2002). Improved quantitative real-time RT-PCR for expression profiling of
individual cells. Nucleic Acids Res. 30, e89. doi: 10.1093/nar/gnf088
Liss, B., Haeckel, O., Wildmann, J., Miki, T., Seino, S., and Roeper, J. (2005). K-ATP
channels promote the differential degeneration of dopaminergic midbrain
neurons. Nat. Neurosci. 8, 1742–1751. doi: 10.1038/nn1570
Lopreiato, R., Giacomello, M., and Carafoli, E. (2014). The plasma membrane
calcium pump: new ways to look at an old enzyme. J. Biol. Chem. 289,
10261–10268. doi: 10.1074/jbc.O114.555565
Ludolph, A. C., Brettschneider, J., and Weishaupt, J. H. (2012).
Amyotrophic lateral sclerosis. Curr. Opin. Neurol. 25, 530–535. doi:
10.1097/WCO.0b013e328356d328
Mallilankaraman, K., Cárdenas, C., Doonan, P. J., Chandramoorthy, H. C., Irrinki,
K. M., Golenár, T., et al. (2012a). MCUR1 is an essential component of mito-
chondrial Ca2+ uptake that regulates cellular metabolism. Nat. Cell Biol. 14,
1336–1343. doi: 10.1038/ncb2622
Mallilankaraman, K., Doonan, P., Cárdenas, C., Chandramoorthy, H. C., Müller,
M., Miller, R., et al. (2012b). MICU1 is an essential gatekeeper for MCU-
mediated mitochondrial Ca(2+) uptake that regulates cell survival. Cell 151,
630–644. doi: 10.1016/j.cell.2012.10.011
Marchi, S., and Pinton, P. (2014). The mitochondrial calcium uniporter com-
plex: molecular components, structure and physiopathological implications.
J. Physiol. 592(Pt 5), 829–839. doi: 10.1113/jphysiol.2013.268235
Martin, L. J. (2011). Mitochondrial pathobiology in ALS. J. Bioenerg. Biomembr. 43,
569–579. doi: 10.1007/s10863-011-9395-y
Matus, S., Valenzuela, V., Medinas, D.B., and Hetz, C. (2013). ER dysfunc-
tion and protein folding stress in ALS. Int. J. Cell Biol. 2013:674751. doi:
10.1155/2013/674751
McCormack, J. G., and Denton, R. M. (1990). The role of mitochondrial Ca2+
transport and matrix Ca2+ in signal transduction in mammalian tissues.
Biochim. Biophys. Acta 1018, 287–291. doi: 10.1016/0005-2728(90)90269-A
McGoldrick, P., Joyce, P. I., Fisher, E. M. C., and Greensmith, L. (2013).
Rodent models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1832,
1421–1436. doi: 10.1016/j.bbadis.2013.03.012
Mendonça, D. M. F., Chimelli, L., and Martinez, A. M. B. (2006). Expression of
ubiquitin and proteasome in motorneurons and astrocytes of spinal cords from
patients with amyotrophic lateral sclerosis. Neurosci. Lett. 404, 315–319. doi:
10.1016/j.neulet.2006.06.009
Murakami, T., Nagai, M., Miyazaki, K., Morimoto, N., Ohta, Y., Kurata, T., et al.
(2007). Early decrease of mitochondrial DNA repair enzymes in spinal motor
neurons of presymptomatic transgenic mice carrying a mutant SOD1 gene.
Brain Res. 1150, 182–189. doi: 10.1016/j.brainres.2007.02.057
Muyderman, H., and Chen, T. (2014). Mitochondrial dysfunction in amy-
otrophic lateral sclerosis—a valid pharmacological target? Br. J. Pharmacol. 171,
2191–2205. doi: 10.1111/bph.12476
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C.,
Chou, T. T., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar
degeneration and amyotrophic lateral sclerosis. Science 314, 130–133. doi:
10.1126/science.1134108
Nguyen, K. T., García-Chacón, L. E., Barrett, J. N., Barrett, E. F., and David,
G. (2009). The Psi(m) depolarization that accompanies mitochondrial Ca2+
uptake is greater in mutant SOD1 than in wild-type mouse motor terminals.
Proc. Natl. Acad. Sci. U.S.A. 106, 2007–2011. doi: 10.1073/pnas.0810934106
Nowikovsky, K., Pozzan, T., Rizzuto, R., Scorrano, L., and Bernardi, P.
(2012). Perspectives on: SGP symposium on mitochondrial physiology and
medicine: the pathophysiology of LETM1. J. Gen. Physiol. 139, 445–454. doi:
10.1085/jgp.201110757
Palty, R., Silverman, W. F., Hershfinkel, M., Caporale, T., Sensi, S. L., Parnis, J., et al.
(2010). NCLX is an essential component of mitochondrial Na+/Ca2+ exchange.
Proc. Natl. Acad. Sci. U.S.A. 107, 436–441. doi: 10.1073/pnas.0908099107
Parpura, V., Heneka, M. T., Montana, V., Oliet, S. H. R., Schousboe, A., Haydon, P.
G., et al. (2012). Glial cells in (patho)physiology. J. Neurochem. 121, 4–27. doi:
10.1111/j.1471-4159.2012.07664.x
Frontiers in Cellular Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 353 | 13
Mühling et al. Calcium-transporter expression in SOD1 ALS-mice
Pasinelli, P., Houseweart, M. K., Brown, R. H., and Cleveland, D. W. (2000).
Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn
superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc.
Natl. Acad. Sci. U.S.A. 97, 13901–13906. doi: 10.1073/pnas.240305897
Paxinos, G., and Franklin, K. B. (2001). The Mouse Brain in Stereotaxic Coordinates,
2nd Edn. San Diego: Academic Press.
Peixoto, P. M., Kim, H.-J., Sider, B., Starkov, A., Horvath, T. L., and Manfredi, G.
(2013). UCP2 overexpression worsens mitochondrial dysfunction and acceler-
ates disease progression in a mouse model of amyotrophic lateral sclerosis.Mol.
Cell. Neurosci. 57, 104–110. doi: 10.1016/j.mcn.2013.10.002
Perocchi, F., Gohil, V. M., Girgis, H. S., Bao, X. R., McCombs, J. E., Palmer, A. E.,
et al. (2010). MICU1 encodes a mitochondrial EF hand protein required for
Ca2+ uptake. Nature 467, 291–296. doi: 10.1038/nature09358
Pignataro, G., Boscia, F., Esposito, E., Sirabella, R., Cuomo, O., Vinciguerra, A.,
et al. (2012). NCX1 and NCX3: two new effectors of delayed preconditioning in
brain ischemia. Neurobiol. Dis. 45, 616–623. doi: 10.1016/j.nbd.2011.10.007
Puri, S., and Hebrok, M. (2012). Diabetic β cells: to be or not to be? Cell 150,
1103–1104. doi: 10.1016/j.cell.2012.08.021
Qiang, L., Fujita, R., and Abeliovich, A. (2013). Remodeling neurodegeneration:
somatic cell reprogramming-based models of adult neurological disorders.
Neuron 78, 957–969. doi: 10.1016/j.neuron.2013.06.002
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L.
P., et al. (2006). Hereditary parkinsonism with dementia is caused by muta-
tions in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38,
1184–1191. doi: 10.1038/ng1884
Renton, A. E., Chiò, A., and Traynor, B. J. (2013). State of play in amyotrophic
lateral sclerosis genetics. Nat. Neurosci. 17, 17–23. doi: 10.1038/nn.3584
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs,
J. R., et al. (2011). A hexanucleotide repeat expansion in C9ORF72 is
the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257–268. doi:
10.1016/j.neuron.2011.09.010
Rizzuto, R., and Pozzan, T. (2006). Microdomains of intracellular Ca2+: molecu-
lar determinants and functional consequences. Physiol. Rev. 86, 369–408. doi:
10.1152/physrev.00004.2005
Rotunno, M. S., and Bosco, D. A. (2013). An emerging role for misfolded wild-
type SOD1 in sporadic ALS pathogenesis. Front. Cell. Neurosci. 7:253. doi:
10.3389/fncel.2013.00253
Sarthy, P. V., Fu, M., and Huang, J. (1991). Developmental expression of the glial
fibrillary acidic protein (GFAP) gene in the mouse retina. Cell. Mol. Neurobiol.
11, 623–637. doi: 10.1007/BF00741450
Schiemann, J., Schlaudraff, F., Klose, V., Bingmer, M., Seino, S., Magill, P. J.,
et al. (2012). K-ATP channels in dopamine substantia nigra neurons control
bursting and novelty-induced exploration. Nat. Neurosci. 15, 1272–1280. doi:
10.1038/nn.3185
Schlaudraff, F., Gründemann, J., Fauler, M., Dragicevic, E., Hardy, J., and Liss,
B. (2014). Orchestrated increase of dopamine and PARK mRNAs but not
miR-133b in dopamine neurons in Parkinson’s disease. Neurobiol. Aging 35,
2302–2315. doi: 10.1016/j.neurobiolaging.2014.03.016
Sharma, V., and O’Halloran, D. M. (2014). Recent structural and functional
insights into the family of sodium calcium exchangers. Genesis 52, 93–109. doi:
10.1002/dvg.22735
Solomon, J. A., Tarnopolsky, M. A., Hamadeh, M. J., and Dawson, T. M. (2011).
One Universal Common endpoint in mouse models of amyotrophic lateral
sclerosis. PLoS ONE 6:e20582. doi: 10.1371/journal.pone.0020582
Strehler, E. E. (2013). Plasma membrane calcium ATPases as novel candidates for
therapeutic agent development. J. Pharm. Pharm. Sci. 16, 190–206.
Tadic, V., Prell, T., Lautenschlaeger, J., and Grosskreutz, J. (2014). The ER
mitochondria calcium cycle and ER stress response as therapeutic tar-
gets in amyotrophic lateral sclerosis. Front. Cell. Neurosci. 8:147. doi:
10.3389/fncel.2014.00147
Trenker, M., Malli, R., Fertschai, I., Levak-Frank, S., and Graier, W. F. (2007).
Uncoupling proteins 2 and 3 are fundamental for mitochondrial Ca2+ uniport.
Nat. Cell Biol. 9, 445–452. doi: 10.1038/ncb1556
Valori, C. F., Brambilla, L., Martorana, F., and Rossi, D. (2014). The multifaceted
role of glial cells in amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 71, 287–297.
doi: 10.1007/s00018-013-1429-7
Van Den Bosch, L. (2011). Genetic rodent models of amyotrophic lateral sclerosis.
J. Biomed. Biotechnol. 2011:348765. doi: 10.1155/2011/348765
Van Den Bosch, L., Vandenberghe, W., Klaassen, H., van Houtte, E., and
Robberecht, W. (2000). Ca(2+)-permeable AMPA receptors and selective vul-
nerability of motor neurons. J. Neurol. Sci. 180, 29–34. doi: 10.1016/S0022-
510X(00)00414-7
Vehviläinen, P., Koistinaho, J., and Gundars, G. (2014). Mechanisms of mutant
SOD1 induced mitochondrial toxicity in amyotrophic lateral sclerosis. Front.
Cell Neurosci. 8:126. doi: 10.3389/fncel.2014.00126
Vinsant, S., Mansfield, C., Jimenez-Moreno, R., Del Gaizo Moore, V., Yoshikawa,
M., Hampton, T. G., et al. (2013a). Characterization of early pathogenesis in
the SOD1(G93A) mouse model of ALS: part I, background and methods. Brain
Behav. 3, 335–350. doi: 10.1002/brb3.143
Vinsant, S., Mansfield, C., Jimenez-Moreno, R., Del Gaizo Moore, V., Yoshikawa,
M., Hampton, T. G., et al. (2013b). Characterization of early pathogenesis in
the SOD1(G93A) mouse model of ALS: part II, results and discussion. Brain
Behav. 3, 431–457. doi: 10.1002/brb3.142
von Lewinski, F., and Keller, B. U. (2005). Ca2+, mitochondria and selective
motoneuron vulnerability: implications for ALS. Trends Neurosci. 28, 494–500.
doi: 10.1016/j.tins.2005.07.001
Vucic, S., Rothstein, J. D., and Kiernan, M. C. (2014). Advances in treating
amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends
Neurosci. 37, 433–442. doi: 10.1016/j.tins.2014.05.006
Waldeck-Weiermair, M., Jean-Quartier, C., Rost, R., Khan, M. J., Vishnu, N.,
Bondarenko, A. I., et al. (2011). Leucine zipper EF hand-containing trans-
membrane protein 1 (Letm1) and uncoupling proteins 2 and 3 (UCP2/3)
contribute to two distinct mitochondrial Ca2+ uptake pathways. J. Biol. Chem.
286, 28444–28455. doi: 10.1074/jbc.M111.244517
Wegorzewska, I., and Baloh, R. H. (2011). TDP-43-based animal models of
neurodegeneration: new insights into ALS pathology and pathophysiology.
Neurodegener. Dis. 8, 262–274. doi: 10.1159/000321547
Wiederkehr, A., Szanda, G., Akhmedov, D., Mataki, C., Heizmann, C. W.,
Schoonjans, K., et al. (2011). Mitochondrial matrix calcium is an acti-
vating signal for hormone secretion. Cell Metab. 13, 601–611. doi:
10.1016/j.cmet.2011.03.015
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 01 August 2014; paper pending published: 29 September 2014; accepted: 08
October 2014; published online: 14 November 2014.
Citation: Mühling T, Duda J, Weishaupt JH, Ludolph AC and Liss B (2014) Elevated
mRNA-levels of distinct mitochondrial and plasma membrane Ca2+ transporters in
individual hypoglossal motor neurons of endstage SOD1 transgenic mice. Front. Cell.
Neurosci. 8:353. doi: 10.3389/fncel.2014.00353
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2014 Mühling, Duda, Weishaupt, Ludolph and Liss. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permit-
ted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Cellular Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 353 | 14
